From April 2003 to December 2006, 195 patients with de novo symptomatic myeloma and less than 60 years of age, were randomly assigned to receive either tandem transplantation up-front [Arm A, n=97] or one autologous stem cell transplantation followed by a maintenance therapy with thalidomide (day +90, 100 mg per day during 6 months) [Arm B, n=98]. Patients included in arm B received a second transplant at disease progression. In both arms, autologous stem cell transplantation was preceded by first-line therapy with thalidomide-dexamethasone and subsequent collection of peripheral blood stem cells with high-dose cyclophosphamide (4 g/m(2)) and granulocyte colony stimulating factor. Data were analyzed on an intent-to-treat basis. With a median follow-up of 33 months (range, 6-46 months), the 3-year overall survival was 65% in arm A, and 85% in arm B (P= .04). The 3-year progression-free survival was 57% in arm A, and 85% in arm B (P= .02). Up-front single autologous transplant followed by 6 months of maintenance therapy with thalidomide (with second transplant in reserve for relapse or progression) is an effective therapeutic strategy to treat multiple myeloma patients, and appears superior to tandem transplant in this setting. This study was registered at www.ClinicalTrails.gov (NCT 00207805).
Mendeley saves you time finding and organizing research
There are no full text links
Choose a citation style from the tabs below